What is LLY's current stock price?

As of now, LLY is trading at $827.52, with a daily change of +0.52%.

What are the risks associated with LLY stock?

LLY Key risk is its Low Risk Level, .

What is LLY next earnings date?

LLY next earnings report is scheduled for Oct 30, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

LLY Stock Analysis & IQ Rating | Eli Lilly and

LLY

Eli Lilly and

$827.52

+$6.35 | +0.52%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 935.63

MKT CAP

$ 781.34B

52W Low

$ 623.78

VOL

$ 1.68M

P/E Ratio

53.92

AVG VOL

$ 3.54M

RSI

58.42

TREND

Uptrend

alert Latest Updates

OptionSpotter 04:31 AM

Constellation Energy is lighting up the options tape today and not by accident. When institutional traders pile in this aggressively, it’s usually because they see what the rest of us don’t. Up 6% and trending strong, CEG ...

LLY Stock IQ

Login to see Eli Lilly and (LLY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

LLY Target Price

Login to display

Strengths

LLY Rewards

Earnings are forecast to grow

LLY Rewards

Investors confidence is positive

LLY Rewards

Upgraded on attractively valued

LLY Rewards

Trading below its fair value

Chart

$725.42 (+14.07%)

$762.33 (+8.55%)

$765.84 (+8.05%)

$797.45 (+3.77%)

1year

6month

3month

1month

LLY Risk Level

LLY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

LLY Analysts Opinion

LLY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

LLY Analysts Opinion

LLY Analysts opinion is positive and also has improved from the past 3 months

LLY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

83%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

90%

LLY Street Opinion

LLY Street view is extremely bullish and have positive views on the near-term outlook

LLY Performance Sentiment

Sentiments overview associated with LLY events and the stock performance.

83%

12%

Positive

Negative

54 out of 65
events present

8 out of 65
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$819.59

Resistance
Price

$714.59

Current Price Range

$855.35

Show methods +

LLY Earnings

The TTM reflects 12-month period, providing review of LLY financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

53,258

45,043

34,124

+24.93%

Cost of Revenue

9,247

8,418

7,082

+14.27%

Gross Profit

44,012

36,624

27,042

+27.58%

Operating Exp

21,129

19,123

16,255

+14.01%

Operating Inc

22,882

17,502

10,787

+45.65%

Net Interest Inc

-730

-605

-312

-

Interest Exp

910

781

486

+36.84%

Interest Inc

180

175

174

+1.71%

Other Inc Exp

-5,293

-4,216

-3,920

-

EPS Growth

15.35

11.80

5.83

+62.26%

LLY Financial Health

The company financial health has moderately improved over the past year

Financial Score

4.14

Next Earnings Date: Oct 30, 2025

Linked to LLY

IQ

Close Price

Change

NVO

4.09

52.96

-0.48%

SNY

3.91

51.64

+4.28%

PFE

4.08

24.76

+0.36%

NVS

4.26

130.36

-0.97%

ABBV

4.16

227.99

+0.04%

LLY Latest Analysis +

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections. ) and ADVM) on Friday announced that they have entered into a definitive under which Lilly will acquire Adverum Biotechnologies including its lead product Ixo-vec.Under the merger terms Eli Lilly will launch a tender offer to acquire all outstanding Adverum shares for up to $12.47 per share consisting of $3.56 in cash at closing and a non-transferable contingent value right (CVR) worth up to $8.91 per share tied to future

Today

$827.52 | +0.52%

Activity

Eli Lilly Options Trading: A Deep Dive into Market Sentiment. Whales with a lot of money to spend have taken a noticeably ish stance on Looking at options history for Eli Lilly (NYSE:) we detected 30 trades.If we consider the specifics of each trade it is accurate to state that 50% of the investors opened trades with ish expectations and 23% with bearish.From the overall spotted trades 5 are puts for a total amount of $180992 and 25 calls for a total amount of $2461645.After evaluating the tradi

Today

$827.52 | +0.52%

Activity

Jim Cramer on Eli Lilly: They Need to Have Something Else to Come Out. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a callers query about the stock during the episode Cramer said: Heres the problem with Lilly: they need to have something else to come out. They need something thats big that the insurance companies will cover for their [….]

Today

$827.52 | +0.52%

Activity

2 Things Investors Should Know About Eli Lillys $5 Billion Investment to Improve Its Drug Production Capacity. Key PointsEli Lillys new United States facility will be just the first of four that it plans to build in the country.

Today

$827.52 | +0.52%

Activity

Potential

Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24 Companies and 26 Therapies | DelveInsight. Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24 Companies and 26 Therapies |. DelveInsightThe hidradenitis suppurativa market is poised for strong growth driven by increasing disease awareness earlier diagnosis and expanding treatment access. Advances in biologic and targeted therapies particularly the emergen

Thu Oct 23, 2025

$821.04 | +1.06%

Activity

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?. Lilly (LLY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$821.04 | +1.06%

Earnings

Potential

Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?. Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17 J.P. Morgan analyst Chris Schott maintained a ish stance on Eli Lilly and Company (NYSE:LLY) keeping his Buy rating. The same day Eli Lilly and Company (NYSE:LLY) announced results from the primary overall [….]

Thu Oct 23, 2025

$821.04 | +1.06%

Activity

Potential

Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager. Key PointsSold 6430 shares of Eli Lilly and Company. estimated transaction value ~$4.78 million

Wed Oct 22, 2025

$812.43 | +1.61%

Activity

Heres How Much $100 Invested In Eli Lilly 20 Years Ago Would Be Worth Today. Eli Lilly (NYSE:) has outperformed the market over the past 20 years by 5.81% on an annualized basis producing an average annual return of 14.88%. Currently Eli Lilly has a market capitalization of $718.41 billion.

Mon Oct 20, 2025

$808.96 | +0.70%

Activity

RANI: Chugai Deal Announced. By With investors perched on the edge of their seats for months Rani Therapeutics Holdings Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront payment the potential for $75 million in technology transfer and development milestones $100 million in sales milestones and single digit royaltie

Mon Oct 20, 2025

$808.96 | +0.70%

Activity

Potential

FAQ About LLY Stock Insights

What is LLY current stock price?

What are LLY stock strengths?

What risks are associated with LLY stock?

When is LLY next earnings report?

What is LLY market cap and volume?

What is LLY's current Stock IQ?

Should I buy LLY stock right now?

Is LLY a Strong Buy right now?

What does a 'Strong Buy' rating mean for LLY?

What does a 'Strong Sell' rating mean for LLY?

What factors influence LLY's Stock IQ?

Explore our LLY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored LLY Stock Strategies
Effective Risk Management

FIND US ON

Receive our LLY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

LLY

Eli Lilly and

Current Price

$827.52

+$6.35 | +0.52%

52W High

$ 935.63

MKT CAP

$ 781.34B

52W Low

$ 623.78

VOL

$ 1.68M

P/E Ratio

53.92

AVG VOL

$ 3.54M

RSI

58.42

TREND

Uptrend

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

LLY Rewards

Earnings are forecast to grow

LLY Rewards

Investors confidence is positive

LLY Rewards

Upgraded on attractively valued

LLY Rewards

Trading below its fair value

Linked to LLY

Symbol

IQ

Close

Change

NVO

4.09

52.96

-0.48%

SNY

3.91

51.64

+4.28%

PFE

4.08

24.76

+0.36%

NVS

4.26

130.36

-0.97%

ABBV

4.16

227.99

+0.04%

LLY Stock IQ

Login to unlock Eli Lilly and (LLY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$725.42 (+14.07%)

$762.33 (+8.55%)

$765.84 (+8.05%)

$797.45 (+3.77%)

1year

6month

3month

1month

LLY Analysts Opinion

LLY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

LLY Analysts Opinion

LLY Analysts opinion is positive and also has improved from the past 3 months

LLY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

83%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

90%

LLY Street Opinion

LLY Street view is extremely bullish and have positive views on the near-term outlook

LLY Risk Level

LLY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

LLY Performance Sentiment

Sentiments overview associated with LLY events and the stock performance.

83%

12%

Positive

Negative

54 out of 65
events present

8 out of 65
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$819.59

Resistance
Price

$714.59

Current Price Range

$855.35

Show methods +

LLY Earnings

The TTM data reflects the most recent 12-month period, providing overview of LLY financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

53,258

45,043

34,124

+24.93%

Cost of Revenue

9,247

8,418

7,082

+14.27%

Gross Profit

44,012

36,624

27,042

+27.58%

Operating Exp

21,129

19,123

16,255

+14.01%

Operating Inc

22,882

17,502

10,787

+45.65%

Net Interest Inc

-730

-605

-312

-

Interest Exp

910

781

486

+36.84%

Interest Inc

180

175

174

+1.71%

Other Inc Exp

-5,293

-4,216

-3,920

-

EPS Growth

15.35

11.80

5.83

+62.26%

LLY Financial Health

The company financial health has moderately improved over the past year

Financial Score

4.14

Next Earnings Date: Oct 30, 2025

LLY Latest Analysis

OptionSpotter 04:31 AM

Constellation Energy is lighting up the options tape today and not by accident. When institutional traders pile in this aggressively, it’s usually because they see what the rest of us don’t. Up 6% and trending strong, CEG ...

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections. ) and ADVM) on Friday announced that they have entered into a definitive under which Lilly will acquire Adverum Biotechnologies including its lead product Ixo-vec.Under the merger terms Eli Lilly will launch a tender offer to acquire all outstanding Adverum shares for up to $12.47 per share consisting of $3.56 in cash at closing and a non-transferable contingent value right (CVR) worth up to $8.91 per share tied to future

Today

$827.52 | +0.52%

Activity

Eli Lilly Options Trading: A Deep Dive into Market Sentiment. Whales with a lot of money to spend have taken a noticeably ish stance on Looking at options history for Eli Lilly (NYSE:) we detected 30 trades.If we consider the specifics of each trade it is accurate to state that 50% of the investors opened trades with ish expectations and 23% with bearish.From the overall spotted trades 5 are puts for a total amount of $180992 and 25 calls for a total amount of $2461645.After evaluating the tradi

Today

$827.52 | +0.52%

Activity

Jim Cramer on Eli Lilly: They Need to Have Something Else to Come Out. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a callers query about the stock during the episode Cramer said: Heres the problem with Lilly: they need to have something else to come out. They need something thats big that the insurance companies will cover for their [….]

Today

$827.52 | +0.52%

Activity

2 Things Investors Should Know About Eli Lillys $5 Billion Investment to Improve Its Drug Production Capacity. Key PointsEli Lillys new United States facility will be just the first of four that it plans to build in the country.

Today

$827.52 | +0.52%

Activity

Potential

Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24 Companies and 26 Therapies | DelveInsight. Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24 Companies and 26 Therapies |. DelveInsightThe hidradenitis suppurativa market is poised for strong growth driven by increasing disease awareness earlier diagnosis and expanding treatment access. Advances in biologic and targeted therapies particularly the emergen

Thu Oct 23, 2025

$821.04 | +1.06%

Activity

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?. Lilly (LLY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$821.04 | +1.06%

Earnings

Potential

Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?. Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17 J.P. Morgan analyst Chris Schott maintained a ish stance on Eli Lilly and Company (NYSE:LLY) keeping his Buy rating. The same day Eli Lilly and Company (NYSE:LLY) announced results from the primary overall [….]

Thu Oct 23, 2025

$821.04 | +1.06%

Activity

Potential

Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager. Key PointsSold 6430 shares of Eli Lilly and Company. estimated transaction value ~$4.78 million

Wed Oct 22, 2025

$812.43 | +1.61%

Activity

Heres How Much $100 Invested In Eli Lilly 20 Years Ago Would Be Worth Today. Eli Lilly (NYSE:) has outperformed the market over the past 20 years by 5.81% on an annualized basis producing an average annual return of 14.88%. Currently Eli Lilly has a market capitalization of $718.41 billion.

Mon Oct 20, 2025

$808.96 | +0.70%

Activity

RANI: Chugai Deal Announced. By With investors perched on the edge of their seats for months Rani Therapeutics Holdings Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner-funded asset development. On October 18th Rani and Chugai Pharmaceutical disclosed a collaboration and license agreement that includes a $10 million upfront payment the potential for $75 million in technology transfer and development milestones $100 million in sales milestones and single digit royaltie

Mon Oct 20, 2025

$808.96 | +0.70%

Activity

Potential

Discover LLY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of LLY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our LLY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

LLY Stock trends

LLY Stock performance

LLY Stock analysis

LLY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing LLY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing LLY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

LLY Stock Analysis & IQ Rating | Eli Lilly and

LLY Stock IQ

LLY Target Price

LLY Risk Level

LLY Analysts Opinion

LLY Street Consensus

LLY Performance Sentiment

Technical Price Levels

LLY Financial Health

Explore our LLY Stock insights

Receive our LLY Daily Alerts

LLY Stock IQ

LLY Street Consensus

LLY Risk Level

Technical Price Levels

Discover LLY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of LLY. We're here to help you make informed investment decisions today.

Receive our LLY Daily Alerts

LLY Runner Alarm